Sarepta Therapeutics Inc
SRPT
Company Profile
Business description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Contact
215 First Street
Suite 415
CambridgeMA02142
USAT: +1 617 274-4000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,314
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,465.00 | 44.50 | 0.53% |
| CAC 40 | 7,379.40 | 1.34 | -0.02% |
| DAX 40 | 19,985.54 | 76.40 | 0.38% |
| Dow JONES (US) | 42,844.31 | 300.09 | 0.71% |
| FTSE 100 | 8,256.00 | 82.98 | 1.02% |
| HKSE | 19,623.32 | 436.63 | -2.18% |
| NASDAQ | 19,475.97 | 165.18 | 0.86% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,925.40 | 43.77 | 0.74% |
| S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
| SSE Composite Index | 3,262.56 | 89.20 | -2.66% |